Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Portfolio Pulse from Avi Kapoor
Wall Street analysts have updated their price targets and ratings for several companies. Piper Sandler raised Itron's target and upgraded the stock, while HC Wainwright cut targets for Cara Therapeutics and Kronos Bio but maintained Buy ratings. JP Morgan downgraded PepsiCo and lowered its target. BMO Capital raised Amgen's target and upgraded the stock. Stifel downgraded Vertex Energy and cut its target. Keybanc raised Uber's target and maintained an Overweight rating. Raymond James lowered Mirum Pharmaceuticals' target but kept a Strong Buy rating. Piper Sandler also raised Sunrun's target and upgraded the stock. Baird downgraded Masonite International and cut its target.
December 19, 2023 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Baird downgraded Masonite International from Outperform to Neutral and lowered the price target from $106 to $92.
The downgrade to Neutral and decreased price target by Baird could result in a negative short-term impact on Masonite International's stock.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 80
NEGATIVE IMPACT
JP Morgan downgraded PepsiCo from Overweight to Neutral and reduced the price target from $185 to $176.
The downgrade and lower price target by JP Morgan could lead to a negative short-term reaction in PepsiCo's stock price.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 80
NEGATIVE IMPACT
Stifel downgraded Vertex Energy from Buy to Hold and cut the price target from $6 to $4.
The downgrade to Hold and reduced price target by Stifel could negatively affect Vertex Energy's stock in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 80
NEUTRAL IMPACT
HC Wainwright cut Cara Therapeutics' price target from $7 to $2.5 but maintained a Buy rating.
The drastic price target reduction could be negative, but the maintained Buy rating suggests underlying optimism, possibly mitigating the short-term impact.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 70
NEUTRAL IMPACT
HC Wainwright cut Kronos Bio's price target from $9 to $2.5 but maintained a Buy rating.
The significant price target reduction could negatively impact the stock, but the maintained Buy rating suggests some optimism, potentially balancing the short-term impact.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 70
NEUTRAL IMPACT
Raymond James reduced Mirum Pharmaceuticals' price target from $78 to $64 but maintained a Strong Buy rating.
The price target cut could be seen negatively, but the Strong Buy rating may indicate that the long-term outlook remains positive, leading to a neutral short-term impact.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 70
POSITIVE IMPACT
BMO Capital upgraded Amgen from Market Perform to Outperform and increased the price target from $286 to $326.
The upgrade to Outperform and raised price target by BMO Capital could result in a positive short-term impact on Amgen's stock.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Piper Sandler upgraded Itron from Neutral to Overweight and raised the price target from $72 to $91.
The upgrade and significant price target raise by Piper Sandler could lead to increased investor confidence and a potential short-term rally in Itron's stock.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Piper Sandler increased Sunrun's price target from $15 to $31 and upgraded the stock from Neutral to Overweight.
The upgrade and substantial price target increase by Piper Sandler could lead to increased investor interest and a potential short-term rise in Sunrun's stock price.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Keybanc raised Uber's price target from $61 to $70 and maintained an Overweight rating.
The increased price target and continued Overweight rating by Keybanc could lead to a bullish short-term impact on Uber's stock.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90